EA202193117A1 - КОМБИНИРОВАННЫЕ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К EGFR/c-MET И 3-ГО ПОКОЛЕНИЯ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ EGFR - Google Patents

КОМБИНИРОВАННЫЕ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К EGFR/c-MET И 3-ГО ПОКОЛЕНИЯ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ EGFR

Info

Publication number
EA202193117A1
EA202193117A1 EA202193117A EA202193117A EA202193117A1 EA 202193117 A1 EA202193117 A1 EA 202193117A1 EA 202193117 A EA202193117 A EA 202193117A EA 202193117 A EA202193117 A EA 202193117A EA 202193117 A1 EA202193117 A1 EA 202193117A1
Authority
EA
Eurasian Patent Office
Prior art keywords
egfr
tyrosine kinase
kinase inhibitors
combination therapies
met antibodies
Prior art date
Application number
EA202193117A
Other languages
English (en)
Russian (ru)
Inventor
Сильви Лакерр
Мэттью Лоренци
Шери Мурс
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/en
Publication of EA202193117A1 publication Critical patent/EA202193117A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202193117A 2019-05-14 2020-05-14 КОМБИНИРОВАННЫЕ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К EGFR/c-MET И 3-ГО ПОКОЛЕНИЯ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ EGFR EA202193117A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
EA202193117A1 true EA202193117A1 (ru) 2022-02-11

Family

ID=78716450

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193117A EA202193117A1 (ru) 2019-05-14 2020-05-14 КОМБИНИРОВАННЫЕ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К EGFR/c-MET И 3-ГО ПОКОЛЕНИЯ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ EGFR

Country Status (12)

Country Link
EP (1) EP3968985A4 (https=)
JP (2) JP2022531980A (https=)
KR (1) KR20220010731A (https=)
CN (1) CN113840601A (https=)
AU (1) AU2020275272A1 (https=)
BR (1) BR112021022828A2 (https=)
CA (1) CA3140360A1 (https=)
EA (1) EA202193117A1 (https=)
IL (1) IL287962A (https=)
MA (1) MA55978A (https=)
MX (1) MX2021013955A (https=)
SG (1) SG11202112412QA (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024346227A1 (en) * 2023-09-21 2026-04-09 Beijing Neox Biotech Limited Multi-specific antibodies and uses thereof
TW202519556A (zh) * 2023-09-28 2025-05-16 大陸商上海翰森生物醫藥科技有限公司 雙特異性抗體在製備治療癌症的藥物中的用途
CN120271706A (zh) * 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
RU2601892C2 (ru) * 2008-03-06 2016-11-10 Дженентек, Инк. Комбинированная терапия антагонистами с-мет и egfr
DK2560993T3 (da) * 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN113201073A (zh) * 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
SG11202108311RA (en) * 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies

Also Published As

Publication number Publication date
BR112021022828A2 (pt) 2022-04-12
JP2022531980A (ja) 2022-07-12
EP3968985A1 (en) 2022-03-23
KR20220010731A (ko) 2022-01-26
SG11202112412QA (en) 2021-12-30
CA3140360A1 (en) 2020-11-19
AU2020275272A1 (en) 2021-12-02
MA55978A (fr) 2022-03-23
JP2025118606A (ja) 2025-08-13
IL287962A (en) 2022-01-01
EP3968985A4 (en) 2023-07-26
MX2021013955A (es) 2022-03-11
CN113840601A (zh) 2021-12-24

Similar Documents

Publication Publication Date Title
JOP20210304A1 (ar) علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
SA519410710B1 (ar) أجسام مضادة خاصة لأجل flt3 واستخداماتها
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
JOP20210233A1 (ar) علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
EA201990548A1 (ru) Лечение кластерной головной боли
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201690502A1 (ru) Замещенные пиримидиновые ингибиторы bmi-1
MX2021015882A (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden.
EA201991876A1 (ru) Антитела против фактора d и их применения
EA202193117A1 (ru) КОМБИНИРОВАННЫЕ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К EGFR/c-MET И 3-ГО ПОКОЛЕНИЯ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ EGFR
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
MX2019011585A (es) Anticuerpos miltiespecificos estables.
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
EA202092947A1 (ru) Анти-pvrig/анти-tigit биспецифические антитела и способы их применения
EA202192089A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ И СТРАТИФИКАЦИЯ ПАЦИЕНТОВ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К РЕЦЕПТОРАМ EGFR И c-Met